# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 ...
Cantor Fitzgerald analyst Rick Bienkowski reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and maintains $65...
Truist Securities analyst Joon Lee maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $120 price target.
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Cantor Fitzgerald analyst Rick Bienkowski reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and maintains $65...
NTLA-2001 is an investigational in vivo CRISPR-based gene editing therapy designed to be a single-dose treatment for transthyre...
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, Cle...